|
Volumn 30, Issue 4, 2000, Pages 679-683
|
Practice guidelines for the management of patients with blastomycosis
a b d e f |
Author keywords
[No Author keywords available]
|
Indexed keywords
AMPHOTERICIN B;
ANTIFUNGAL AGENT;
FLUCONAZOLE;
HYDROXYSTILBAMIDINE;
ITRACONAZOLE;
KETOCONAZOLE;
PYRROLE DERIVATIVE;
BLASTOMYCES DERMATITIDIS;
BLASTOMYCOSIS;
CENTRAL NERVOUS SYSTEM DISEASE;
CLINICAL FEATURE;
CLINICAL TRIAL;
DISEASE COURSE;
DISEASE SEVERITY;
DRUG EFFICACY;
DRUG INDUCED DISEASE;
DRUG SAFETY;
DRUG TOLERABILITY;
FOLLOW UP;
FUNGUS CULTURE;
HUMAN;
IMMUNE DEFICIENCY;
IMMUNOCOMPETENCE;
INTERSTITIAL PNEUMONIA;
LABORATORY DIAGNOSIS;
LOBAR PNEUMONIA;
MEDICAL SOCIETY;
NONHUMAN;
PRACTICE GUIDELINE;
PREGNANCY;
PRIORITY JOURNAL;
REVIEW;
AMPHOTERICIN B;
ANTIFUNGAL AGENTS;
AZOLES;
BLASTOMYCES;
BLASTOMYCOSIS;
COST-BENEFIT ANALYSIS;
FEMALE;
HUMAN;
IMMUNOCOMPROMISED HOST;
LUNG DISEASES;
OPPORTUNISTIC INFECTIONS;
OUTCOME ASSESSMENT (HEALTH CARE);
PREGNANCY;
PREGNANCY COMPLICATIONS, INFECTIOUS;
|
EID: 0033801556
PISSN: 10584838
EISSN: None
Source Type: Journal
DOI: 10.1086/313750 Document Type: Review |
Times cited : (194)
|
References (21)
|